Loading publication...
A stalled deal isn’t a lost opportunity, but an absence of forward motion (with a plausible-sounding reason and a timeline no one can pin down). The updates say the deal is in review, or that the slow timeline is part of the normal internal process. But with every passing week, the executive's priorities shift a little further, and the momentum that took months to build drains away. At companies that sell medical devices, technology, and services to major health systems, this is not an edge case.
Loading publication...